Ontology highlight
ABSTRACT:
SUBMITTER: Kim M
PROVIDER: S-EPMC6125211 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Kim Minjee M Ma Daniel J DJ Calligaris David D Zhang Shuangling S Feathers Ryan W RW Vaubel Rachael A RA Meaux Isabelle I Mladek Ann C AC Parrish Karen E KE Jin Fang F Barriere Cedric C Debussche Laurent L Watters James J Tian Shulan S Decker Paul A PA Eckel-Passow Jeanette E JE Kitange Gaspar J GJ Johnson Aaron J AJ Parney Ian F IF Anastasiadis Panos Z PZ Agar Nathalie Y R NYR Elmquist William F WF Sarkaria Jann N JN
Molecular cancer therapeutics 20180703 9
Controversy exists surrounding whether heterogeneous disruption of the blood-brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. <i>In vitro</i> efficacy of SAR405838 was evaluated in P ...[more]